American Chemical Society--233rd National Meeting. 25-29 March 2007, Chicago, IL, USA.
Turner
Ben
B
Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK. ben.turner@thomson.com
Bright
Jonathan
J
D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy; D015740:Calcitonin Gene-Related Peptide / Q000037:antagonists & inhibitors; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D016503:Drug Delivery Systems; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D039222:Integrin alpha1beta1 / Q000037:antagonists & inhibitors; D009422:Nervous System Diseases / Q000188:drug therapy; D054390:Receptors, CCR2; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D026941:Sodium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use
D018759:Adrenergic Uptake Inhibitors; D015740:Calcitonin Gene-Related Peptide; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D015507:Drugs, Investigational; D039222:Integrin alpha1beta1; D054390:Receptors, CCR2; D019707:Receptors, Chemokine; D017367:Selective Serotonin Reuptake Inhibitors; D026941:Sodium Channel Blockers; C515334:CCR2 protein, human